SAS Output

19-NOV-2017 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 663 264 90 0 0 BREAST
        9383 663 264 90 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 230 99 36 2 0  
      3 Endocrine Therapy Alone 2536 232 100 38 2 0  
        5083 462 199 74 4 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 705 202 92 47 17 5 BREAST
      2 Blinded drug + Endocrine 711 213 103 57 13 2  
        1416 415 195 104 30 7  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 4 3 3 3 1 1 SURV
      2 Randomization Non-surgical M 3 3 3 2 2 0  
      3 Patient Choice Surgery 37 21 12 5 2 1  
      4 Patient Choice Non-surgical M 80 46 27 11 4 1  
        124 73 45 21 9 3  
 
S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 122 54 24 14 5 1 LUNG
      2 Nivolumab 123 54 23 13 5 1  
        245 108 47 27 10 2  
 
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 2 Y 2 FDA approved regimen 678 430 168 26 0 0 MELAN
      3 MK-3475 (Pembrolizumab) 667 409 157 27 0 0  
        1345 839 325 53 0 0  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 348 338 153 61 18 10 CCD
      2 Site randomized: Control 218 218 148 69 23 8  
      3 SiteRand Int Risk: CSF 297 297 201 113 34 13  
      4 SiteRand Int Risk: No CSF 222 222 163 88 19 7  
        1085 1075 665 331 94 38  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 133 122 82 42 13 3 CCD
        133 122 82 42 13 3  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 111 111 83 51 21 5 BREAST
        111 111 83 51 21 5  
 
  2 Y 2 Observation 50 50 43 26 13 2  
      3 MK-3475 (Pembrolizumab) 44 44 33 17 5 3  
        94 94 76 43 18 5  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 2 2 2 2 2 1 SURV
        2 2 2 2 2 1  
 
  2 Y 1 Carvedilol 1 1 1 1 1 1  
      3 Observation 1 1 1 1 1 1  
        2 2 2 2 2 2  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 17 17 13 9 3 1 GU
      2 Tokyo-172 BCG 16 16 14 9 3 1  
      3 Prime + Tokyo-172 BCG 18 18 16 11 6 2  
        51 51 43 29 12 4  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 425 137 72 30 17 2 PREV
        425 137 72 30 17 2  
 
  1 Y 1 Blinded drug 45 15 6 2 0 0  
      2 Blinded drug 36 9 0 0 0 0  
      3 Blinded drug 35 10 0 0 0 0  
      4 Blinded drug 48 21 11 5 0 0  
        164 55 17 7 0 0